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Abstract: Semiconductor quantum dots (QDs) are a new class of ﬂ  uorescent labels with broad 
applications in biomedical imaging, disease diagnostics, and molecular and cell biology. In 
comparison with organic dyes and ﬂ  uorescent proteins, quantum dots have unique optical and 
electronic properties such as size-tunable light emission, improved signal brightness, resistance 
against photobleaching, and simultaneous excitation of multiple ﬂ  uorescence colors. Recent 
advances have led to multifunctional nanoparticle probes that are highly bright and stable 
under complex in vitro and in vivo conditions. New designs involve encapsulating luminescent 
QDs with amphiphilic block copolymers, and linking the polymer coating to tumor-targeting 
ligands and drug-delivery functionalities. These improved QDs have opened new possibilities 
for real-time imaging and tracking of molecular targets in living cells, for multiplexed analysis 
of biomolecular markers in clinical tissue specimens, and for ultrasensitive imaging of malig-
nant tumors in living animal models. In this article, we brieﬂ  y discuss recent developments in 
bioafﬁ  nity QD probes and their applications in molecular proﬁ  ling of individual cancer cells 
and clinical tissue specimens.
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Introduction
The ability to study molecular and cellular events by using ﬂ  uorescent probes has 
broadly impacted many areas in biomedical research including cell biology, molecular 
biology, drug screening, and molecular diagnostics. However, traditional ﬂ  uorophores 
such as organic dyes and ﬂ  uorescent proteins suffer from several intrinsic problems 
including rapid photobleaching, spectral cross talking, narrow excitation proﬁ  les, and 
limited brightness/signal intensity. In contrast, semiconductor quantum dots (QDs) are 
ﬂ  uorescent nanoparticles based on entirely different principles, and exhibit novel opti-
cal and electronic properties that are not available from organic dyes and ﬂ  uorescent 
proteins. These properties include size- and composition-tunable emission from visible 
to infrared wavelengths, large absorption coefﬁ  cients across a wide spectral range, 
and improved signal brightness and photostability (Alivisatos et al 2005). Due to their 
broad excitation proﬁ  les and narrow/symmetric emission spectra, high-quality QDs 
are also well suited for multiplexed tagging or encoding, in which multiple colors and 
intensities are combined to encode thousands of genes, proteins, or small-molecule 
compounds (Han et al 2001).
These properties have raised new opportunities for analyzing a panel of genes 
and proteins in cancer cells and clinical tissue specimens. Previous work in cancer 
molecular proﬁ  ling has revealed a strong correlation between biomolecular signatures 
(or biomarkers) and cancer behavior (Liotta and Petricoin 2000). However, clinical tumor 
specimens (especially human breast and prostate tumors) are highly heterogeneous, 
containing a mixture of benign, cancerous, and stromal cells. Current technologies International Journal of Nanomedicine 2006:1(4) 474
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for molecular proﬁ  ling include RT-PCR, gene chips, protein 
chips, two-dimensional gel electrophoresis, biomolecular mass 
spectrometry (eg, MALDI-MS, ES-MS, and SELDI-MS), 
but these technologies are not designed to handle this type of 
cellular heterogeneities (Liotta and Petricoin 2000). Also, these 
techniques are “destructive” because they require cells and 
tissue specimens to be processed into a homogeneous solution, 
leading to a loss of valuable 3-D cellular and tissue morpho-
logical information associated with the original tumor.
The development of nanotechnology, especially bio-
conjugated nanoparticles, could provide an essential link by 
which biomarkers are functionally correlated with disease 
behavior (Ferrari 2005). In particular, QD probes can be used 
to quantify a panel of biomarkers on intact cancer cells and 
tissue specimens, allowing a correlation of traditional histo-
pathology and molecular signatures for the same materials 
(Gao et al 2003). This integration may be achieved with 
a spectral imaging microscope that is designed to operate 
both in the morphological staining mode and the molecular 
proﬁ  ling mode. In the following, we discuss the novel optical 
properties of QDs, recent advances in probe development, 
and their applications in molecular analysis of intact cancer 
cells and tissue specimens.
Quantum dots
For use in biology and medicine, QD probes most frequently 
take the form shown in Figure 1, with an inorganic semicon-
ductor core surrounded by a monolayer of ligands and an 
amphiphilic polymer coat that is linked to biomolecules. QD 
cores are most commonly prepared from cadmium selenide 
(CdSe), a binary semiconductor with size-dependent bandgap 
energy that can be tuned to emit light of any color throughout 
the visible spectrum. CdSe QDs have been thoroughly studied 
and can be produced in large quantities with ﬂ  uorescence 
emission efﬁ  ciencies as high as 90% at room temperature 
(Qu and Peng 2002; Pan et al 2005; Yin and Alivisatos 
2005). These crystalline CdSe cores are synthesized and 
capped with a protective zinc sulﬁ  de (ZnS) shell in a high 
temperature organic solvent ( Murray et al 1993; Hines and 
Guyot-Sionnest 1996; Dabbousi et al 1997), and are coated 
with a monolayer of nonpolar coordinating ligands such as 
trioctylphosphine oxide (TOPO).
After synthesis, the nonpolar, hydrophobic QDs are 
transferred to an aqueous phase, a nontrivial process that is 
crucial to the generation of high-quality QDs. Amphiphilic 
polymers, such as polyethylene glycol (PEG)-modiﬁ  ed lipids 
and octylamine-modiﬁ  ed polyacrylic acid (Dubertret et al 
2002; Wu et al 2003), have been used to produce water-soluble 
QDs that maintain the optical properties and colloidal stability 
of the original nanoparticles. Previous phase transfer methods 
involved an exchange of the TOPO ligands for hydrophilic 
ligands, resulting in QDs with reduced quantum yields and 
a tendency to aggregate. After transfer to water, QDs may 
be cross-linked to a variety of biologically active molecules 
such as antibodies, enzymes, nucleic acids, small molecule 
inhibitors, or biologically inert PEG. Many coupling schemes 
have been used to generate cross-links, such as electrostatic 
adsorption (Mattoussi et al 2000), covalent bond formation 
(Chan and Nie 1998; Wu et al 2003), and biomolecular bridg-
ing via streptavidin-biotin binding (Goldman et al 2002; Wu 
et al 2003). These methods give rise to QD probes that are 
highly stable and have excellent afﬁ  nity toward their targets, 
although it is difﬁ  cult to control the number and orientation 
of biomolecules attached to a single QD.
In comparison with organic dyes and ﬂ  uorescent protein, 
QDs have several advantages and unique applications. 
First, QDs have large molar extinction coefﬁ  cients on the 
order of 0.5–5 × 106 M −1cm−1 (Leatherdale et al 2002), 
about 10–50 times larger than that (5–10 × 104 M−1cm−1) of 
organic dyes. Thus, QDs are 10–50 times more efﬁ  cient in 
adsorbing photons than organic dyes at the same excitation 
photon ﬂ  ux, leading a signiﬁ  cant improvement in probe 
brightness. Second, QDs are several thousand times more 
stable against photobleaching than dye molecules, allow-
ing extended imaging and quantitative biomarker studies 
of cells and tissue specimens. Third, QDs have size- and 
composition-tunable ﬂ  uorescence emission from visible to 
infrared wavelengths, and one light source can be used to 
excite multiple colors of ﬂ  uorescence emission. This leads 
to very large Stokes spectral shifts (measured by the distance 
between the excitation and emission peaks) that can be used 
to further improve detection sensitivity. This factor becomes 
especially important for clinical tissue studies and in-vivo 
animal imaging due to the high autoﬂ  uorescence background 
often seen in complex biomedical specimens. Indeed, the 
Stokes shifts of semiconductor QDs can be hundreds of 
nanometers, depending on the wavelength of the excita-
tion light. Organic dye signals are often buried by strong 
tissue autoﬂ  uorescence, whereas QD signals can be readily 
separated from the background by wavelength-resolved or 
spectral imaging (Gao et al 2004).
Imaging and tracking of cellular 
events
Live cell imaging often involves transgenic expression of 
ﬂ  uorescently tagged proteins (Miyawaki et al 2003), but this International Journal of Nanomedicine 2006:1(4) 475
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technique is labor-intensive and the resulting ﬂ  uorescent 
proteins are not sufﬁ  ciently bright or stable for single-
molecule imaging and tracking. To address this problem, 
recent work has shown that QDs microinjected into the 
cytoplasm of a single cell of a frog embryo could maintain 
stable and bright ﬂ  uorescence over long periods of excitation 
and observation, allowing real time imaging of embryonic 
development and cellular tracking (Dubertret et al 2002). 
Importantly, injection of a large number of QD particles 
into an individual cell did not appear to negatively impact 
embryonic development or cause toxicity. In 2004, Derfus 
et al (2004) demonstrated that QDs conjugated to organelle-
targeted peptides could translocate to either nuclei or 
mitochondria following microinjection into the cytoplasm. 
Microinjection is, however, a labor-intensive technique and 
requires delicate manipulation of one cell at a time. Other 
techniques for QD delivery across cellular membranes 
include chemical-mediated transfection (cationic peptides, 
cationic lipids, transferrin proteins) and electroporation 
(Chen and Gerion 2004; Derfus et al 2004; Jaiswal et al 
2004). Many types of cells are also able to engulf or take 
up QDs spontaneously via endocytosis, which has led to 
a QD-based cellular motility assay (Pellegrino et al 2003; 
Voura et al 2004) as well as imaging of cancer cell extrava-
sation in living animals (Voura et al 2004). However, these 
delivery methods are all hampered by aggregation of QDs in 
the cytoplasm or trapping of the QD probes in endosomes, 
vesicles, and other intracellular organelles. Working with 
largely aggregated QDs, Nan et al (2005) measured the 
motions of multi-protein molecular machines such as kinesin 
and dynein. By tracking the paths of cationic peptide-conju-
gated QDs inside cells, their data showed directional, non-
Brownian motion that was consistent with the involvement 
of molecular motors. Recent work in our own lab has shown 
that cellular membrane pores formed by bacterial toxins like 
streptolysin O (SLO) are large enough to allow the diffusion 
of single QDs into the cellular cytoplasm, while maintaining 
cellular viability. A major ﬁ  nding is that the SLO-delivered 
QD probes are primarily single dots and they maintain their 
ﬂ  uorescence and blinking characteristics. Figure 2 shows 
confocal ﬂ  uorescence images of single dots and aggregates 
in the cytoplasm of live ﬁ  broblast cells.
It is also signiﬁ  cant that QD probes have been used 
to image and track cell surface proteins with consider-
able success. In particular, Lidke et al (2004) conjugated 
epidermal growth factor (EGF) to QDs in order to ﬂ  uores-
cently image the binding of EGF to erbB/HER receptors on 
the membranes of cells. The authors were able to observe 
individual blinking QDs on the cell surface (corresponding 
to single receptor molecules), and record the endocytosis 
and endosomal trafﬁ  cking of the receptors in real time. The 
high photostability and brightness of these probes made pos-
sible the observation of a previously unreported transport 
mechanism from cellular ﬁ  lopodia to the cell body (Lidke 
et al 2005). Similarly, Dahan et al (2003) reported that QDs 
conjugated to antibody fragments against the GlyR receptor 
could be used to observe single receptors on the membranes 
of neurons. The use of QD probes has allowed real-time 
imaging and tracking of single receptor molecules over an 
extended period of time.
Moleculr proﬁ  ling of individual 
cancer cells
Several groups have used multicolor QD probes for molecu-
lar proﬁ  ling of ﬁ  xed cancer cells. Wu et al reported the 
potential of QDs in 2001 with a variety of multicolor labeling 
experiments on ﬁ  xed cells, demonstrating signiﬁ  cant sensi-
tivity and photostability of QD probes compared to the best 
available organic dyes (Wu et al 2003). Now that these probes 
are commercially available, their superiority to conventional 
dyes has been well established in many ﬁ  xed cell labeling 
experiments. With their narrow emission bandwidths, QDs 
have also been used to simultaneously label up to 5 biomark-
ers on the same ﬁ  xed cells, a task that is nearly impossible 
with conventional dyes due to ﬂ  uorophore crosstalk and the 
need for multiple excitation sources. In another development, 
QDs have been used to simultaneously label ﬁ  xed cells for 
mRNA and protein, combining immunocytochemistry and 
ﬂ  uorescence in situ hybridization (Matsuno et al 2005). 
Furthermore, QDs have been used as dual-modality imag-
ing probes, showing bright contrast in ﬂ  uorescent micro-
graphs of cells and tissues, and their corresponding electron 
micrographs (Nisman et al 2004; Giepmans et al 2005). It 
is clear that QD probes have opened new possibilities in 
multiplexed analysis of cellular biomarkers or antigens. As 
an example, Figure 3 shows color ﬂ  uorescence images of 
human prostate cancer cells that were stained with up to ﬁ  ve 
QD colors, allowing multiplexed analysis of up to ﬁ  ve tumor 
antigens on single intact cancer cells.
It is also important to note that the use of multiplexed 
QD probes further allows spatial mapping of tumor antigens 
on single cells. For example, Figure 4 shows ﬂ  uorescence 
images of single breast cancer cells labeled with a cocktail 
of antibody-QD probes, together with control PBMC 
cells that do not express the tumor antigens. Remarkably, International Journal of Nanomedicine 2006:1(4) 476
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Figure 1 (A) Schematic representation of bioafﬁ  nity quantum dot probes for biological imaging. A CdSe core is surrounded by a ZnS shell that is passivated by hydrophobic 
TOPO ligands and encapsulated in an amphiphilic polymer. Conjugated PEG molecules serve to reduce nonspeciﬁ  c adsorption, and streptavidin provides a high-afﬁ  nity linker 
for conjugation to biotinylated proteins, nucleic acids, or other molecules. (B) Transmission electron micrograph (TEM) of water-soluble quantum dots showing an electron-
dense QD core (dark) and a polymer coating as a lighter shade surrounding each QD. (C) Fluorescence micrograph showing that single QDs can be readily observed when 
the dots are spread on a glass cover slip.
A B
Figure 2 Fluorescence images of single quantum dots and aggregates in the cytoplasm of live ﬁ  broblast cells. (A) Single QDs observed in the cytoplasm after delivery via 
SLO toxin. (B) QD aggregates observed in the cytoplasm after a long period of time following SLO delivery (40 hours). Microtubules were visualized by GFP-tubulin protein 
expression. Both images were obtained with a spinning disk confocal microscope (Perkin Elmer), with the focal plane near the center of each cell.International Journal of Nanomedicine 2006:1(4) 477
Cancer molecular proﬁ  ling with quantum dots
Figure 3 Color ﬂ  uorescence images of human prostate cancer cells stained with multicolor QD-antibody conjugates. (a) Staining of membrane antigen E-cadherin 
with QD655 (emission wavelength = 655 nm); (b) staining of cytoplasmic antigen vimentin with QD525; (c) staining of nuclear antigen HIF1alpha with QD655; and 
(d) multiplexed staining of tumor antigens with QD525 (labeling RANKL), 565(N-cadherin), 605(EF1aplha), 655(E-cadherin) and 705 (vimentin). The cell nuclei were 
counterstained blue with DAPI in (a) and (b).
a. c.
b. d.
(A) (C)
(D)
(E)
(F)
(B)
Figure 4 Multiplexed QD staining and spatial mapping of tumor antigens on single breast cancer cells. (a) Breast tumor BT-474 cell, and (b) breast tumor BT-20 cell; both 
were stained with cytokeratin-QD (green), Her-2-QD (yellow), epithelial speciﬁ  c antigen-QD (red), and the nuclear dye DAPI (blue). Control data: (c) BT-474 cancer cells 
treated with QDs conjugated to nonspeciﬁ  c bovine serum albumin, and (d) peripheral blood mononuclear cells (PBMC) treated with the same QD-antibody conjugates 
used in panels (a) and (b). (e) Fluorescence image of BT-474 cells labeled with FITC-conjugated antibody against cytokeratin, and (f) photobleached image after 20 seconds.International Journal of Nanomedicine 2006:1(4) 478
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Figure 5 Multiplexed QD proﬁ  ling of four tumor biomarkers using two FFPE prostate cancer cell lines with distinct bone-metastasis behaviors. The four markers, all associ-
ated with epithelial-mesenchymal transition (EMT), are N-cadherin, EF (elongation factor)-1alpha, E-cadherin, and vimentin, and their corresponding QD colors are 565 nm, 
605 nm, 655 nm, and 705 nm. The cell nuclei were counterstained blue by DAPI, and the spectra were captured under blue excitation. (a) Color ﬂ  uorescence image of highly 
metastatic prostate cancer cells (clone ARCaPm); (b) single-cell ﬂ  uorescence spectrum obtained from image (a); (c) color ﬂ  uorescence image of benign prostate cancer cells 
(clone ARCaPe); (d) single-cell spectrum obtained from image (c). The relative abundance of these markers is consistent with previous western blotting data (not shown). 
Note that individual cancer cells have heterogeneous expression patterns, that the single-cell data in (b) and (d) are representative of a heterogeneous cell population.
Figure 6 Multiplexed QD staining of archived FFPE clinical specimen from human prostate cancer patients, and comparison between two different glands on the same tis-
sue specimen. Four tumor biomarkers (mdm-2, p53, EGR-1 and p21) were labeled with four colors of QDs emitting at 565 nm, 605 nm, 655nm , and 705 nm respectively. (a) 
Color ﬂ  uorescence image of QD-stained tissue specimens showing just one gland; (b) representative ﬂ  uorescence spectrum obtained from single cells in the gland (image 
a); (c) color ﬂ  uorescence image of the same QD-stained tissue specimens but showing a different gland; (d) representative ﬂ  uorescence spectrum obtained from single cells 
in the second gland (image c). Note that the biomarker proﬁ  le is remarkably different for different glands. This ability to measure cellular heterogeneity on the same tumor 
specimen will be crucial for clinical applications. AF stands for autoﬂ  uorescence.
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all three colors were observed from breast tumor cells (a and 
b), while no QD binding was detected with either the control 
QDs (c) or the control PBMC cells (d). Due to antigen cluster-
ing and colocalization, ﬂ  uorescence imaging showed overlap-
ping Her-2 and epithelial speciﬁ  c antigen (ESA or EpCam) 
signals on the surface of BT-474 cells (a). The BT-20 cells 
were found to have a ring of expressed ESA on the cellular
peripherals and a much lower level of Her-2. In contrast 
to stable QD signals, ﬂ  uorescence from dye-labeled cells 
was photobleached in less than 20 seconds (e and f), pre-
venting quantitative imaging or spectroscopic studies at the 
single-cell level. QDs are considerably brighter and more 
photostable than organic ﬂ  uorophores, which should allow 
sensitive detection of low-abundance cellular targets through 
signal averaging and background subtraction. For statistical 
studies of heterogeneous cell populations, we measured more 
than 100 cancer cells with a ﬂ  uorescence microscope and a 
spectrometer. The results reveal that the BT-474 cells are 
clustered in a “high Her-2” area, and that BT-20 cells are 
clustered in a “low Her-2” area. In clinical samples, a panel 
of selected markers could be analyzed to provide information 
on disease staging and treatment options.
Clinical tissue specimens 
and correlation with tumor behavior
A major application of quantum dots will be in multiplexed 
labeling and molecular analysis of pathological tissue 
specimens. In comparison with single cells, clinical tissue 
specimens are often highly heterogeneous (containing dif-
ferent cell populations in various microenvironments) and 
are much more difﬁ  cult to analyze. Taking advantage of the 
high photostability of QDs, Tokumasu and Dvorak (2003) 
were able to collect 40 consecutive optical sections using 
confocal microscopy and generated a 3-D reconstructed, 
high-resolution image of the membrane domain band 3 in 
erythrocytes. Ness et al (2003) developed an immunohisto-
chemical protocol that combines conventional enzymatic 
signal ampliﬁ  cation and QD labeling to detect intracellular 
antigens in rat and mouse brain tissue sections. Their study 
showed that QD immunoﬂ  uorescence labeling had greater 
sensitivity than similar IHC approaches using conventional 
dyes (Ness et al 2003). Wu et al (2003) developed reli-
able and speciﬁ  c QD probes to localize the breast cancer 
cell surface marker Her2, cytoskeleton ﬁ  bers, and nuclear 
antigens in ﬁ  xed cells, live cells, and tissue sections, with 
a substantial increase in brightness and photostability as 
compared to organic dyes. Taking advantage of the supe-
rior photostability of QDs, Ferrara et al (2006) were able to 
obtain a 3D visualization of the vascular endothelium from 
an en face preparation of human coronary artery by taking 
large z-stacks series. All these studies demonstrate that QDs 
are excellent probes with improved signal-to-noise ratios, 
and are well suited for studying complex biological problems 
(Alivisatos et al 2005).
Most studies on QD ﬂ  uorescent labeling have been 
carried out with cells (both live and ﬁ  xed) (Tokumasu and 
Dvorak 2003; Wu et al 2003; Lidke et al 2004) or freshly 
harvested tissues (Ness et al 2003; Ferrara et al 2006). 
However, most available clinical specimens are archived, 
formalin ﬁ  xed, parafﬁ  n-embedded (FFPE) tissues that might 
be several decades old. Since the clinical outcomes of these 
tissues are already known, it will be great value to use these 
specimens for examining the relationship between molecular 
proﬁ  le and clinical outcome. Compared with cells or animal 
tissues, archived clinical specimens need special treatment 
such as antigen retrieval, and their background autoﬂ  uo-
rescence is generally much stronger than that observed in 
cells. Our group has developed highly successful procedures 
for QD staining of archival FFPE tissue specimens. One 
example is to study the epithelial-mesenchymal transition 
(EMT) process in the progression of prostate cancer to the 
bone. EMT is a normal biological mechanism ﬁ  rst reported 
in embryonic development and later found to be involved in 
cancer metastasis (Huber et al 2005). During EMT, cancer 
cells undergo phenotypical changes and become more 
invasive, characterized by changes in the proﬁ  le change 
of cellular adhesion molecules, particularly, an increase 
of N-cadherin and a loss of E-cadherin. Other important 
markers include the cytoskeleton proteins vimentin, cyto-
keratin 18 and RANKL. In one example, we have used 
QD-conjugated secondary antibodies (Qdots Corporation, 
now Invitrogen) for molecular profiling of two FFPE 
androgen-repressed prostate cancer (ARCaP) cells lines. 
These two cell lines were selected because they represent 
two phenotypes at the two ends of the EMT process during 
prostate cancer progression. The ARCaPE is more epithe-
lial-like and less invasive, while the ARCaPM has more 
mesenchymal characteristics and more invasive (Zhau et al 
1996). Our QD staining studies have achieved simultaneous 
staining of 4 different biomarkers with expression proﬁ  les 
consistent with western blot data (Figure 5). Moreover, QD 
staining also provides spatial localization information (both 
inter- and intracellular) which is not possible with western 
blot or any molecular biology techniques. We have also 
found that staining of FFPE cells requires longer incubation 
time (overnight at 4oC vs 1 hour at room temperature) and International Journal of Nanomedicine 2006:1(4) 480
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a higher QD-secondary antibody concentration than that 
required for freshly ﬁ  xed cells.
For molecular profiling of clinical FFPE prostate 
specimens, we also selected four tumor antigens (mdm-2, 
p53, EGR-1 and p21) as a model system for technology 
development. These markers are known to be important 
in prostate cancer diagnosis and are correlated with tumor 
behavior (Hernandez et al 2003; Mora et al 2005). As shown 
in Figure 6, we were able to detect all 4-markers in the tissue 
specimens, but the autoﬂ  uorescence was higher than that 
observed in FFPE cells. Compared with FFPE cells, clinical 
tissue specimens may require harsher antigen retrieval con-
ditions (EDTA buffer vs citrate buffer) and generally have 
stronger autoﬂ  uorescence. On the other hand, autoﬂ  uores-
cence can be desirable by serving as counterstaining of tissue 
morphology. Autoﬂ  uorescence can be separated from the QD 
signal by intentionally illuminating the sample to bleach it 
out while leaving the QDs bright enough for imaging and 
spectral analysis. Of course, spectral unmixing algorithms 
can be developed or obtained commercially (Mansﬁ  eld et al 
2005) to separate the background ﬂ  uorescence from the real 
QD signals. In summary, these results demonstrate the feasi-
bility of using QDs as ﬂ  uorescent labels for molecular proﬁ  l-
ing of FFPE clinical specimens. With continuous efforts in 
optimizing the experimental conditions, we believe that QD 
probes hold great promise in multiplexed molecular proﬁ  ling 
of clinical tissue specimens and correlation of biomarkers 
with disease behavior.
In conclusion, semiconductor quantum dots have 
emerged as a new class of ﬂ  uorescent tags for molecular 
proﬁ  ling of single cancer cells and clinical tissue specimens. 
With only a single light source, multicolor ﬂ  uorescence 
imaging allows rapid screening and selection of cancer 
cells, and wavelength-resolved spectroscopy provides 
quantitative data on the expression levels of multiple bio-
markers. It should be possible to simultaneously determine 
the expression levels of 8–10 genes or proteins in single 
cells. With spectroscopic multiplexing, it might even be 
possible to analyze 50–100 of genes and proteins on mor-
phologically intact cells or tissue specimens. In addition to 
molecular pathology and in-vitro diagnostics, QD probes 
have shown promise as contrast agents for in vivo tumor 
imaging in living animals (Gao and Nie 2004; Voura et al 
2004; Stroh et al 2005). Thus, we expect QD-based imaging 
and diagnostic technologies to have broad applications in 
linking biomolecular signatures with disease behavior, and 
will play a signiﬁ  cant role in personalized and predictive 
medicine.
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